Compare KORE & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KORE | LEXX |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 16.3M |
| IPO Year | N/A | N/A |
| Metric | KORE | LEXX |
|---|---|---|
| Price | $4.80 | $0.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $1.50 |
| AVG Volume (30 Days) | 40.3K | ★ 1.5M |
| Earning Date | 11-12-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,408,000.00 | $705,923.00 |
| Revenue This Year | $1.26 | $13.35 |
| Revenue Next Year | $7.55 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.06 | ★ 52.05 |
| 52 Week Low | $1.66 | $0.46 |
| 52 Week High | $4.88 | $2.43 |
| Indicator | KORE | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 63.55 | 42.15 |
| Support Level | $4.16 | $0.46 |
| Resistance Level | $4.50 | $0.72 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 90.67 | 49.34 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.